Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow InMed Pharmaceuticals Inc.

Get SEC filing alerts via email and in your feed for InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals develops proprietary small molecule drug candidates targeting the endocannabinoid system to treat high unmet medical needs such as Alzheimer’s disease, dry AMD, and epidermolysis bullosa. The company combines innovative research with diverse manufacturing approaches, including biosynthesis and proprietary platforms, to develop and commercialize pharmaceutical and wellness products. Its core focus is on neuroprotection, anti-inflammatory therapies, and rare cannabinoids for medical and health sectors.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from InMed Pharmaceuticals Inc.

1
1
InMed Pharmaceuticals Inc. InMed Pharmaceuticals Reports $6.7 Million Net Loss, Plans Strategic Shift in Operations

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
InMed Pharmaceuticals Inc. InMed Pharmaceuticals Reports $3.8 Million Net Loss, Revenue Declines 18% in First Half of Fiscal Year

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
InMed Pharmaceuticals Inc. InMed Pharmaceuticals Reports 11% Revenue Decline and Increased Net Loss for Quarter Ending September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
InMed Pharmaceuticals Inc. InMed Pharmaceuticals Reports $8.2 Million Net Loss and $4.9 Million Revenue for Fiscal Year Ending June 30, 2025

Via official filing (AI summary) | 9 months ago | 0 comments

5
1
InMed Pharmaceuticals Inc. InMed Pharmaceuticals Reports Q3 Fiscal 2025 Loss of $2.1 Million, Revenue Increases 8%

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
InMed Pharmaceuticals Inc. InMed Pharmaceuticals Reports $2.6 Million Net Loss in Q2 Fiscal 2025

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
InMed Pharmaceuticals Inc. InMed Pharmaceuticals Reports 40% Revenue Growth, Improved Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments